Top Markets
#1 Islamic Coin Islamic Coin +154.35%
#2 PulseChain PulseChain +49.22%
#3 BOOK OF MEME BOOK OF MEME +24.70%
#4 edgeX edgeX +16.67%
#5 RedStone RedStone +16.49%
#6 Starpower Starpower +15.93%
#7 Bio Protocol Bio Protocol +12.37%
#8 Lighter Lighter +12.26%
#9 Monad Monad +11.98%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.93%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Classement en actions #27803
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Prix de l'action
$0.0492516
Capitalisation boursière
$30.41M
Changement (1 jour)
1.32%
Changement (1 an)
-91.28%
Pays
CN
Échange Immunotech Biopharm Ltd (6978)

Catégorie

Healthcare
Ratio P/B pour Immunotech Biopharm Ltd (6978)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Immunotech Biopharm Ltd, le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Immunotech Biopharm Ltd de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH